Trials / Completed
CompletedNCT00153036
Rt-PA in the Treatment of Acute Ischemic Stroke
ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 821 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rt-PA 0.9 mg/kg verum or placebo Intravenous |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2008-02-01
- First posted
- 2005-09-12
- Last updated
- 2014-05-16
Locations
142 sites across 19 countries: Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00153036. Inclusion in this directory is not an endorsement.